nodes	percent_of_prediction	percent_of_DWPC	metapath
Methylphenidate—Feeling abnormal—Mycophenolic acid—systemic scleroderma	0.000488	0.000488	CcSEcCtD
Methylphenidate—Chest pain—Mycophenolate mofetil—systemic scleroderma	0.000488	0.000488	CcSEcCtD
Methylphenidate—Arthralgia—Mycophenolate mofetil—systemic scleroderma	0.000488	0.000488	CcSEcCtD
Methylphenidate—Myalgia—Mycophenolate mofetil—systemic scleroderma	0.000488	0.000488	CcSEcCtD
Methylphenidate—Myocardial infarction—Prednisone—systemic scleroderma	0.000487	0.000487	CcSEcCtD
Methylphenidate—Breast disorder—Methotrexate—systemic scleroderma	0.000487	0.000487	CcSEcCtD
Methylphenidate—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.000486	0.000486	CcSEcCtD
Methylphenidate—Anxiety—Mycophenolate mofetil—systemic scleroderma	0.000486	0.000486	CcSEcCtD
Methylphenidate—Hypersensitivity—Azathioprine—systemic scleroderma	0.000485	0.000485	CcSEcCtD
Methylphenidate—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000485	0.000485	CcSEcCtD
Methylphenidate—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.000485	0.000485	CcSEcCtD
Methylphenidate—Insomnia—Lisinopril—systemic scleroderma	0.000483	0.000483	CcSEcCtD
Methylphenidate—Discomfort—Mycophenolate mofetil—systemic scleroderma	0.000482	0.000482	CcSEcCtD
Methylphenidate—Paraesthesia—Lisinopril—systemic scleroderma	0.000479	0.000479	CcSEcCtD
Methylphenidate—Vomiting—Captopril—systemic scleroderma	0.000479	0.000479	CcSEcCtD
Methylphenidate—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.000477	0.000477	CcSEcCtD
Methylphenidate—Dyspnoea—Lisinopril—systemic scleroderma	0.000476	0.000476	CcSEcCtD
Methylphenidate—Rash—Captopril—systemic scleroderma	0.000475	0.000475	CcSEcCtD
Methylphenidate—Dermatitis—Captopril—systemic scleroderma	0.000475	0.000475	CcSEcCtD
Methylphenidate—Somnolence—Lisinopril—systemic scleroderma	0.000475	0.000475	CcSEcCtD
Methylphenidate—Headache—Captopril—systemic scleroderma	0.000472	0.000472	CcSEcCtD
Methylphenidate—Confusional state—Mycophenolate mofetil—systemic scleroderma	0.000472	0.000472	CcSEcCtD
Methylphenidate—Dyspepsia—Lisinopril—systemic scleroderma	0.00047	0.00047	CcSEcCtD
Methylphenidate—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.000469	0.000469	CcSEcCtD
Methylphenidate—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.000469	0.000469	CcSEcCtD
Methylphenidate—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	0.000468	0.000468	CcSEcCtD
Methylphenidate—Oedema—Mycophenolate mofetil—systemic scleroderma	0.000468	0.000468	CcSEcCtD
Methylphenidate—Asthma—Methotrexate—systemic scleroderma	0.000466	0.000466	CcSEcCtD
Methylphenidate—Infection—Mycophenolate mofetil—systemic scleroderma	0.000465	0.000465	CcSEcCtD
Methylphenidate—Decreased appetite—Lisinopril—systemic scleroderma	0.000464	0.000464	CcSEcCtD
Methylphenidate—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000461	0.000461	CcSEcCtD
Methylphenidate—Fatigue—Lisinopril—systemic scleroderma	0.00046	0.00046	CcSEcCtD
Methylphenidate—Shock—Mycophenolate mofetil—systemic scleroderma	0.00046	0.00046	CcSEcCtD
Methylphenidate—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.000459	0.000459	CcSEcCtD
Methylphenidate—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	0.000458	0.000458	CcSEcCtD
Methylphenidate—Hypersensitivity—Leflunomide—systemic scleroderma	0.000458	0.000458	CcSEcCtD
Methylphenidate—Pancreatitis—Methotrexate—systemic scleroderma	0.000457	0.000457	CcSEcCtD
Methylphenidate—Pain—Lisinopril—systemic scleroderma	0.000457	0.000457	CcSEcCtD
Methylphenidate—Constipation—Lisinopril—systemic scleroderma	0.000457	0.000457	CcSEcCtD
Methylphenidate—Tachycardia—Mycophenolate mofetil—systemic scleroderma	0.000457	0.000457	CcSEcCtD
Methylphenidate—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.000454	0.000454	CcSEcCtD
Methylphenidate—Bradycardia—Prednisone—systemic scleroderma	0.000454	0.000454	CcSEcCtD
Methylphenidate—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.000452	0.000452	CcSEcCtD
Methylphenidate—Diarrhoea—Azathioprine—systemic scleroderma	0.00045	0.00045	CcSEcCtD
Methylphenidate—Haemoglobin—Prednisone—systemic scleroderma	0.000449	0.000449	CcSEcCtD
Methylphenidate—Nausea—Captopril—systemic scleroderma	0.000448	0.000448	CcSEcCtD
Methylphenidate—Abdominal discomfort—Methotrexate—systemic scleroderma	0.000447	0.000447	CcSEcCtD
Methylphenidate—Haemorrhage—Prednisone—systemic scleroderma	0.000446	0.000446	CcSEcCtD
Methylphenidate—Anorexia—Mycophenolate mofetil—systemic scleroderma	0.000446	0.000446	CcSEcCtD
Methylphenidate—Asthenia—Leflunomide—systemic scleroderma	0.000446	0.000446	CcSEcCtD
Methylphenidate—Hallucination—Prednisone—systemic scleroderma	0.000444	0.000444	CcSEcCtD
Methylphenidate—Pancytopenia—Methotrexate—systemic scleroderma	0.000443	0.000443	CcSEcCtD
Methylphenidate—Feeling abnormal—Lisinopril—systemic scleroderma	0.00044	0.00044	CcSEcCtD
Methylphenidate—Pruritus—Leflunomide—systemic scleroderma	0.00044	0.00044	CcSEcCtD
Methylphenidate—Connective tissue disorder—Prednisone—systemic scleroderma	0.000439	0.000439	CcSEcCtD
Methylphenidate—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.000437	0.000437	CcSEcCtD
Methylphenidate—Dizziness—Azathioprine—systemic scleroderma	0.000435	0.000435	CcSEcCtD
Methylphenidate—Upper respiratory tract infection—Methotrexate—systemic scleroderma	0.000433	0.000433	CcSEcCtD
Methylphenidate—Erectile dysfunction—Methotrexate—systemic scleroderma	0.000429	0.000429	CcSEcCtD
Methylphenidate—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.000426	0.000426	CcSEcCtD
Methylphenidate—Photosensitivity reaction—Methotrexate—systemic scleroderma	0.000425	0.000425	CcSEcCtD
Methylphenidate—Asthenia—Mycophenolic acid—systemic scleroderma	0.000425	0.000425	CcSEcCtD
Methylphenidate—Diarrhoea—Leflunomide—systemic scleroderma	0.000425	0.000425	CcSEcCtD
Methylphenidate—Urticaria—Lisinopril—systemic scleroderma	0.000424	0.000424	CcSEcCtD
Methylphenidate—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.000423	0.000423	CcSEcCtD
Methylphenidate—Abdominal pain—Lisinopril—systemic scleroderma	0.000422	0.000422	CcSEcCtD
Methylphenidate—Body temperature increased—Lisinopril—systemic scleroderma	0.000422	0.000422	CcSEcCtD
Methylphenidate—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	0.00042	0.00042	CcSEcCtD
Methylphenidate—Pruritus—Mycophenolic acid—systemic scleroderma	0.000419	0.000419	CcSEcCtD
Methylphenidate—Vomiting—Azathioprine—systemic scleroderma	0.000418	0.000418	CcSEcCtD
Methylphenidate—Pneumonia—Methotrexate—systemic scleroderma	0.000418	0.000418	CcSEcCtD
Methylphenidate—Eye disorder—Prednisone—systemic scleroderma	0.000417	0.000417	CcSEcCtD
Methylphenidate—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.000417	0.000417	CcSEcCtD
Methylphenidate—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.000416	0.000416	CcSEcCtD
Methylphenidate—Infestation—Methotrexate—systemic scleroderma	0.000416	0.000416	CcSEcCtD
Methylphenidate—Drowsiness—Methotrexate—systemic scleroderma	0.000416	0.000416	CcSEcCtD
Methylphenidate—Infestation NOS—Methotrexate—systemic scleroderma	0.000416	0.000416	CcSEcCtD
Methylphenidate—Rash—Azathioprine—systemic scleroderma	0.000415	0.000415	CcSEcCtD
Methylphenidate—Dermatitis—Azathioprine—systemic scleroderma	0.000414	0.000414	CcSEcCtD
Methylphenidate—Depression—Methotrexate—systemic scleroderma	0.000414	0.000414	CcSEcCtD
Methylphenidate—Flushing—Prednisone—systemic scleroderma	0.000414	0.000414	CcSEcCtD
Methylphenidate—Headache—Azathioprine—systemic scleroderma	0.000412	0.000412	CcSEcCtD
Methylphenidate—Stevens-Johnson syndrome—Methotrexate—systemic scleroderma	0.000412	0.000412	CcSEcCtD
Methylphenidate—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.000412	0.000412	CcSEcCtD
Methylphenidate—Dizziness—Leflunomide—systemic scleroderma	0.000411	0.000411	CcSEcCtD
Methylphenidate—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.000407	0.000407	CcSEcCtD
Methylphenidate—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000406	0.000406	CcSEcCtD
Methylphenidate—Angiopathy—Prednisone—systemic scleroderma	0.000405	0.000405	CcSEcCtD
Methylphenidate—Conjunctivitis—Methotrexate—systemic scleroderma	0.000404	0.000404	CcSEcCtD
Methylphenidate—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000404	0.000404	CcSEcCtD
Methylphenidate—Immune system disorder—Prednisone—systemic scleroderma	0.000403	0.000403	CcSEcCtD
Methylphenidate—Constipation—Mycophenolate mofetil—systemic scleroderma	0.0004	0.0004	CcSEcCtD
Methylphenidate—Pain—Mycophenolate mofetil—systemic scleroderma	0.0004	0.0004	CcSEcCtD
Methylphenidate—Arrhythmia—Prednisone—systemic scleroderma	0.000399	0.000399	CcSEcCtD
Methylphenidate—Sweating—Methotrexate—systemic scleroderma	0.000398	0.000398	CcSEcCtD
Methylphenidate—Haematuria—Methotrexate—systemic scleroderma	0.000396	0.000396	CcSEcCtD
Methylphenidate—Vomiting—Leflunomide—systemic scleroderma	0.000395	0.000395	CcSEcCtD
Methylphenidate—Alopecia—Prednisone—systemic scleroderma	0.000394	0.000394	CcSEcCtD
Methylphenidate—Hypersensitivity—Lisinopril—systemic scleroderma	0.000393	0.000393	CcSEcCtD
Methylphenidate—Hepatobiliary disease—Methotrexate—systemic scleroderma	0.000393	0.000393	CcSEcCtD
Methylphenidate—Dizziness—Mycophenolic acid—systemic scleroderma	0.000392	0.000392	CcSEcCtD
Methylphenidate—Epistaxis—Methotrexate—systemic scleroderma	0.000392	0.000392	CcSEcCtD
Methylphenidate—Rash—Leflunomide—systemic scleroderma	0.000392	0.000392	CcSEcCtD
Methylphenidate—Dermatitis—Leflunomide—systemic scleroderma	0.000391	0.000391	CcSEcCtD
Methylphenidate—Mental disorder—Prednisone—systemic scleroderma	0.000391	0.000391	CcSEcCtD
Methylphenidate—Nausea—Azathioprine—systemic scleroderma	0.000391	0.000391	CcSEcCtD
Methylphenidate—Headache—Leflunomide—systemic scleroderma	0.000389	0.000389	CcSEcCtD
Methylphenidate—Erythema—Prednisone—systemic scleroderma	0.000389	0.000389	CcSEcCtD
Methylphenidate—Malnutrition—Prednisone—systemic scleroderma	0.000389	0.000389	CcSEcCtD
Methylphenidate—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	0.000385	0.000385	CcSEcCtD
Methylphenidate—Asthenia—Lisinopril—systemic scleroderma	0.000383	0.000383	CcSEcCtD
Methylphenidate—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.000383	0.000383	CcSEcCtD
Methylphenidate—Pruritus—Lisinopril—systemic scleroderma	0.000378	0.000378	CcSEcCtD
Methylphenidate—Vomiting—Mycophenolic acid—systemic scleroderma	0.000377	0.000377	CcSEcCtD
Methylphenidate—Haemoglobin—Methotrexate—systemic scleroderma	0.000375	0.000375	CcSEcCtD
Methylphenidate—Rash—Mycophenolic acid—systemic scleroderma	0.000374	0.000374	CcSEcCtD
Methylphenidate—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000373	0.000373	CcSEcCtD
Methylphenidate—Haemorrhage—Methotrexate—systemic scleroderma	0.000373	0.000373	CcSEcCtD
Methylphenidate—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.000372	0.000372	CcSEcCtD
Methylphenidate—Headache—Mycophenolic acid—systemic scleroderma	0.000371	0.000371	CcSEcCtD
Methylphenidate—Pharyngitis—Methotrexate—systemic scleroderma	0.00037	0.00037	CcSEcCtD
Methylphenidate—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	0.00037	0.00037	CcSEcCtD
Methylphenidate—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.00037	0.00037	CcSEcCtD
Methylphenidate—Nausea—Leflunomide—systemic scleroderma	0.000369	0.000369	CcSEcCtD
Methylphenidate—Urinary tract disorder—Methotrexate—systemic scleroderma	0.000368	0.000368	CcSEcCtD
Methylphenidate—Vision blurred—Prednisone—systemic scleroderma	0.000366	0.000366	CcSEcCtD
Methylphenidate—Urethral disorder—Methotrexate—systemic scleroderma	0.000366	0.000366	CcSEcCtD
Methylphenidate—Diarrhoea—Lisinopril—systemic scleroderma	0.000365	0.000365	CcSEcCtD
Methylphenidate—Ill-defined disorder—Prednisone—systemic scleroderma	0.00036	0.00036	CcSEcCtD
Methylphenidate—Visual impairment—Methotrexate—systemic scleroderma	0.000359	0.000359	CcSEcCtD
Methylphenidate—Anaemia—Prednisone—systemic scleroderma	0.000359	0.000359	CcSEcCtD
Methylphenidate—Agitation—Prednisone—systemic scleroderma	0.000357	0.000357	CcSEcCtD
Methylphenidate—Angioedema—Prednisone—systemic scleroderma	0.000355	0.000355	CcSEcCtD
Methylphenidate—Dizziness—Lisinopril—systemic scleroderma	0.000353	0.000353	CcSEcCtD
Methylphenidate—Erythema multiforme—Methotrexate—systemic scleroderma	0.000353	0.000353	CcSEcCtD
Methylphenidate—Nausea—Mycophenolic acid—systemic scleroderma	0.000352	0.000352	CcSEcCtD
Methylphenidate—Malaise—Prednisone—systemic scleroderma	0.00035	0.00035	CcSEcCtD
Methylphenidate—Vertigo—Prednisone—systemic scleroderma	0.000349	0.000349	CcSEcCtD
Methylphenidate—Eye disorder—Methotrexate—systemic scleroderma	0.000349	0.000349	CcSEcCtD
Methylphenidate—Syncope—Prednisone—systemic scleroderma	0.000348	0.000348	CcSEcCtD
Methylphenidate—Cardiac disorder—Methotrexate—systemic scleroderma	0.000346	0.000346	CcSEcCtD
Methylphenidate—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.000345	0.000345	CcSEcCtD
Methylphenidate—Loss of consciousness—Prednisone—systemic scleroderma	0.000341	0.000341	CcSEcCtD
Methylphenidate—Vomiting—Lisinopril—systemic scleroderma	0.000339	0.000339	CcSEcCtD
Methylphenidate—Angiopathy—Methotrexate—systemic scleroderma	0.000338	0.000338	CcSEcCtD
Methylphenidate—Immune system disorder—Methotrexate—systemic scleroderma	0.000337	0.000337	CcSEcCtD
Methylphenidate—Rash—Lisinopril—systemic scleroderma	0.000337	0.000337	CcSEcCtD
Methylphenidate—Convulsion—Prednisone—systemic scleroderma	0.000337	0.000337	CcSEcCtD
Methylphenidate—Dermatitis—Lisinopril—systemic scleroderma	0.000336	0.000336	CcSEcCtD
Methylphenidate—Mediastinal disorder—Methotrexate—systemic scleroderma	0.000336	0.000336	CcSEcCtD
Methylphenidate—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000336	0.000336	CcSEcCtD
Methylphenidate—Hypertension—Prednisone—systemic scleroderma	0.000335	0.000335	CcSEcCtD
Methylphenidate—Chills—Methotrexate—systemic scleroderma	0.000335	0.000335	CcSEcCtD
Methylphenidate—Headache—Lisinopril—systemic scleroderma	0.000334	0.000334	CcSEcCtD
Methylphenidate—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.000331	0.000331	CcSEcCtD
Methylphenidate—Arthralgia—Prednisone—systemic scleroderma	0.000331	0.000331	CcSEcCtD
Methylphenidate—Myalgia—Prednisone—systemic scleroderma	0.000331	0.000331	CcSEcCtD
Methylphenidate—Anxiety—Prednisone—systemic scleroderma	0.00033	0.00033	CcSEcCtD
Methylphenidate—Alopecia—Methotrexate—systemic scleroderma	0.00033	0.00033	CcSEcCtD
Methylphenidate—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.000328	0.000328	CcSEcCtD
Methylphenidate—Discomfort—Prednisone—systemic scleroderma	0.000327	0.000327	CcSEcCtD
Methylphenidate—Mental disorder—Methotrexate—systemic scleroderma	0.000327	0.000327	CcSEcCtD
Methylphenidate—Erythema—Methotrexate—systemic scleroderma	0.000325	0.000325	CcSEcCtD
Methylphenidate—Malnutrition—Methotrexate—systemic scleroderma	0.000325	0.000325	CcSEcCtD
Methylphenidate—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.00032	0.00032	CcSEcCtD
Methylphenidate—Nausea—Lisinopril—systemic scleroderma	0.000317	0.000317	CcSEcCtD
Methylphenidate—Anaphylactic shock—Prednisone—systemic scleroderma	0.000317	0.000317	CcSEcCtD
Methylphenidate—Oedema—Prednisone—systemic scleroderma	0.000317	0.000317	CcSEcCtD
Methylphenidate—Infection—Prednisone—systemic scleroderma	0.000315	0.000315	CcSEcCtD
Methylphenidate—Back pain—Methotrexate—systemic scleroderma	0.000314	0.000314	CcSEcCtD
Methylphenidate—Shock—Prednisone—systemic scleroderma	0.000312	0.000312	CcSEcCtD
Methylphenidate—Nervous system disorder—Prednisone—systemic scleroderma	0.000311	0.000311	CcSEcCtD
Methylphenidate—Tachycardia—Prednisone—systemic scleroderma	0.000309	0.000309	CcSEcCtD
Methylphenidate—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000309	0.000309	CcSEcCtD
Methylphenidate—Skin disorder—Prednisone—systemic scleroderma	0.000308	0.000308	CcSEcCtD
Methylphenidate—Hyperhidrosis—Prednisone—systemic scleroderma	0.000307	0.000307	CcSEcCtD
Methylphenidate—Vision blurred—Methotrexate—systemic scleroderma	0.000306	0.000306	CcSEcCtD
Methylphenidate—Anorexia—Prednisone—systemic scleroderma	0.000302	0.000302	CcSEcCtD
Methylphenidate—Ill-defined disorder—Methotrexate—systemic scleroderma	0.000301	0.000301	CcSEcCtD
Methylphenidate—Anaemia—Methotrexate—systemic scleroderma	0.0003	0.0003	CcSEcCtD
Methylphenidate—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000297	0.000297	CcSEcCtD
Methylphenidate—Rash—Mycophenolate mofetil—systemic scleroderma	0.000295	0.000295	CcSEcCtD
Methylphenidate—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000295	0.000295	CcSEcCtD
Methylphenidate—Headache—Mycophenolate mofetil—systemic scleroderma	0.000293	0.000293	CcSEcCtD
Methylphenidate—Malaise—Methotrexate—systemic scleroderma	0.000293	0.000293	CcSEcCtD
Methylphenidate—Vertigo—Methotrexate—systemic scleroderma	0.000292	0.000292	CcSEcCtD
Methylphenidate—Leukopenia—Methotrexate—systemic scleroderma	0.000291	0.000291	CcSEcCtD
Methylphenidate—Musculoskeletal discomfort—Prednisone—systemic scleroderma	0.000289	0.000289	CcSEcCtD
Methylphenidate—Insomnia—Prednisone—systemic scleroderma	0.000287	0.000287	CcSEcCtD
Methylphenidate—Paraesthesia—Prednisone—systemic scleroderma	0.000285	0.000285	CcSEcCtD
Methylphenidate—Cough—Methotrexate—systemic scleroderma	0.000283	0.000283	CcSEcCtD
Methylphenidate—Convulsion—Methotrexate—systemic scleroderma	0.000281	0.000281	CcSEcCtD
Methylphenidate—Dyspepsia—Prednisone—systemic scleroderma	0.000279	0.000279	CcSEcCtD
Methylphenidate—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000278	0.000278	CcSEcCtD
Methylphenidate—Arthralgia—Methotrexate—systemic scleroderma	0.000276	0.000276	CcSEcCtD
Methylphenidate—Chest pain—Methotrexate—systemic scleroderma	0.000276	0.000276	CcSEcCtD
Methylphenidate—Myalgia—Methotrexate—systemic scleroderma	0.000276	0.000276	CcSEcCtD
Methylphenidate—Decreased appetite—Prednisone—systemic scleroderma	0.000276	0.000276	CcSEcCtD
Methylphenidate—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.000275	0.000275	CcSEcCtD
Methylphenidate—Fatigue—Prednisone—systemic scleroderma	0.000273	0.000273	CcSEcCtD
Methylphenidate—Discomfort—Methotrexate—systemic scleroderma	0.000273	0.000273	CcSEcCtD
Methylphenidate—Constipation—Prednisone—systemic scleroderma	0.000271	0.000271	CcSEcCtD
Methylphenidate—Confusional state—Methotrexate—systemic scleroderma	0.000267	0.000267	CcSEcCtD
Methylphenidate—Anaphylactic shock—Methotrexate—systemic scleroderma	0.000265	0.000265	CcSEcCtD
Methylphenidate—Infection—Methotrexate—systemic scleroderma	0.000263	0.000263	CcSEcCtD
Methylphenidate—Feeling abnormal—Prednisone—systemic scleroderma	0.000261	0.000261	CcSEcCtD
Methylphenidate—Nervous system disorder—Methotrexate—systemic scleroderma	0.00026	0.00026	CcSEcCtD
Methylphenidate—Thrombocytopenia—Methotrexate—systemic scleroderma	0.000259	0.000259	CcSEcCtD
Methylphenidate—Gastrointestinal pain—Prednisone—systemic scleroderma	0.000259	0.000259	CcSEcCtD
Methylphenidate—Skin disorder—Methotrexate—systemic scleroderma	0.000257	0.000257	CcSEcCtD
Methylphenidate—Hyperhidrosis—Methotrexate—systemic scleroderma	0.000256	0.000256	CcSEcCtD
Methylphenidate—Anorexia—Methotrexate—systemic scleroderma	0.000253	0.000253	CcSEcCtD
Methylphenidate—Urticaria—Prednisone—systemic scleroderma	0.000252	0.000252	CcSEcCtD
Methylphenidate—Abdominal pain—Prednisone—systemic scleroderma	0.000251	0.000251	CcSEcCtD
Methylphenidate—Body temperature increased—Prednisone—systemic scleroderma	0.000251	0.000251	CcSEcCtD
Methylphenidate—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	0.000241	0.000241	CcSEcCtD
Methylphenidate—Insomnia—Methotrexate—systemic scleroderma	0.00024	0.00024	CcSEcCtD
Methylphenidate—Paraesthesia—Methotrexate—systemic scleroderma	0.000238	0.000238	CcSEcCtD
Methylphenidate—Dyspnoea—Methotrexate—systemic scleroderma	0.000236	0.000236	CcSEcCtD
Methylphenidate—Somnolence—Methotrexate—systemic scleroderma	0.000236	0.000236	CcSEcCtD
Methylphenidate—Hypersensitivity—Prednisone—systemic scleroderma	0.000234	0.000234	CcSEcCtD
Methylphenidate—Dyspepsia—Methotrexate—systemic scleroderma	0.000233	0.000233	CcSEcCtD
Methylphenidate—Decreased appetite—Methotrexate—systemic scleroderma	0.00023	0.00023	CcSEcCtD
Methylphenidate—Gastrointestinal disorder—Methotrexate—systemic scleroderma	0.000229	0.000229	CcSEcCtD
Methylphenidate—Fatigue—Methotrexate—systemic scleroderma	0.000228	0.000228	CcSEcCtD
Methylphenidate—Asthenia—Prednisone—systemic scleroderma	0.000228	0.000228	CcSEcCtD
Methylphenidate—Pain—Methotrexate—systemic scleroderma	0.000227	0.000227	CcSEcCtD
Methylphenidate—Pruritus—Prednisone—systemic scleroderma	0.000224	0.000224	CcSEcCtD
Methylphenidate—Feeling abnormal—Methotrexate—systemic scleroderma	0.000218	0.000218	CcSEcCtD
Methylphenidate—Diarrhoea—Prednisone—systemic scleroderma	0.000217	0.000217	CcSEcCtD
Methylphenidate—Gastrointestinal pain—Methotrexate—systemic scleroderma	0.000217	0.000217	CcSEcCtD
Methylphenidate—Urticaria—Methotrexate—systemic scleroderma	0.000211	0.000211	CcSEcCtD
Methylphenidate—Dizziness—Prednisone—systemic scleroderma	0.00021	0.00021	CcSEcCtD
Methylphenidate—Abdominal pain—Methotrexate—systemic scleroderma	0.000209	0.000209	CcSEcCtD
Methylphenidate—Body temperature increased—Methotrexate—systemic scleroderma	0.000209	0.000209	CcSEcCtD
Methylphenidate—Vomiting—Prednisone—systemic scleroderma	0.000202	0.000202	CcSEcCtD
Methylphenidate—Rash—Prednisone—systemic scleroderma	0.0002	0.0002	CcSEcCtD
Methylphenidate—Dermatitis—Prednisone—systemic scleroderma	0.0002	0.0002	CcSEcCtD
Methylphenidate—Headache—Prednisone—systemic scleroderma	0.000199	0.000199	CcSEcCtD
Methylphenidate—Hypersensitivity—Methotrexate—systemic scleroderma	0.000195	0.000195	CcSEcCtD
Methylphenidate—Asthenia—Methotrexate—systemic scleroderma	0.00019	0.00019	CcSEcCtD
Methylphenidate—Nausea—Prednisone—systemic scleroderma	0.000188	0.000188	CcSEcCtD
Methylphenidate—Pruritus—Methotrexate—systemic scleroderma	0.000187	0.000187	CcSEcCtD
Methylphenidate—Diarrhoea—Methotrexate—systemic scleroderma	0.000181	0.000181	CcSEcCtD
Methylphenidate—Dizziness—Methotrexate—systemic scleroderma	0.000175	0.000175	CcSEcCtD
Methylphenidate—Vomiting—Methotrexate—systemic scleroderma	0.000168	0.000168	CcSEcCtD
Methylphenidate—Rash—Methotrexate—systemic scleroderma	0.000167	0.000167	CcSEcCtD
Methylphenidate—Dermatitis—Methotrexate—systemic scleroderma	0.000167	0.000167	CcSEcCtD
Methylphenidate—Headache—Methotrexate—systemic scleroderma	0.000166	0.000166	CcSEcCtD
Methylphenidate—Nausea—Methotrexate—systemic scleroderma	0.000157	0.000157	CcSEcCtD
